Active not recruitingPHASE3INTERVENTIONAL

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

This study, called 'A Study of Orforglipron', is exploring a new medicine named orforglipron. Its main goal is to see how well this medicine helps adults who are overweight or have obesity to lose weight, compared to a dummy medicine (placebo). Participants must also have at least one other health problem related to their weight, such as high blood pressure or high cholesterol, but not diabetes. The study aims to understand if orforglipron can be a safe and effective way to manage weight. If you're eligible and interested, taking part would involve about 18 months of commitment to help researchers learn more about this potential new treatment.

At a glance

Status

Active not recruiting

Phase

PHASE3

Sponsor

Eli Lilly and Company

Enrolment target

600

Start

15 May 2025

Estimated completion

01 Aug 2027

Obesity Overweight

What is this study about?

This research study is called 'A Study of Orforglipron' and it's looking into a new medicine for weight management. The medicine is called orforglipron, and it's being tested to see if it can help adults who are overweight or have obesity to lose weight. This study is for people who also have another health condition linked to their weight, such as high blood pressure, high cholesterol, sleep apnoea (a condition where breathing stops and starts while you sleep), or heart disease. It's important to know that this study is not for people with diabetes.

In this study, some participants will receive the active medicine (orforglipron), while others will receive a 'placebo', which looks exactly like the study medicine but contains no active ingredients. This helps researchers understand if any changes seen are truly due to the medicine or other factors. All participants will be carefully monitored throughout the study.

The information gathered from studies like this is really important. It helps scientists and doctors understand if new medicines are safe and effective. If orforglipron proves to be helpful, it could one day become another option for people in the UK looking for support with their weight management and related health conditions.

Key takeaways

This study is testing a new medicine called orforglipron for weight management.
It's for adults with obesity or those who are overweight with certain other health conditions (but not diabetes).
Some participants will receive the active medicine, others a placebo.
The study lasts about 18 months and involves regular clinic visits.
Careful monitoring of your health will be provided throughout the study.

Who may be eligible?

To join this study, you generally need to be an adult (18 years or older) and fit into one of these groups: either you have obesity (meaning your Body Mass Index, or BMI, is 30 or higher), or you are overweight (BMI of 25 or higher) and also have at least one weight-related health issue like high blood pressure, high cholesterol, sleep apnoea, or heart disease. You should also have tried to lose weight with diet before and not been successful.

However, there are also reasons why you might not be able to join. For example, if you have any type of diabetes (Type 1 or Type 2), or if your weight has changed a lot recently. You also can't join if you have serious heart failure or a recent acute heart problem, or if you have certain liver or pancreas conditions. If you're already taking other medicines or remedies specifically for weight loss, you wouldn't be able to participate either.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have a BMI of 30 or higher, OR a BMI of 25 or higher and a weight-related health condition (like high blood pressure, high cholesterol, sleep apnoea, or heart disease)?
Have you tried to lose weight with diet before without success?
Do you NOT have diabetes (Type 1 or Type 2)?
Are you NOT currently taking other weight-loss medicines or remedies?

Answer every question to see your result.

What does participation involve?

If you decide to take part in this study, your involvement will last for about 18 months in total. During this time, you will have regular visits to the study clinic. These visits will involve various health checks, such as measuring your weight, blood pressure, and taking blood samples. You will be given either the study medicine (orforglipron) or a dummy medicine (placebo) to take regularly, as instructed by the study team. They will explain exactly how to take it and what to expect. Throughout the study, the research team will keep a close eye on your health and any changes you experience. It's really important to attend all your scheduled appointments and let the study team know if you have any concerns or feel unwell.

Potential risks and benefits

Participating in a study like this might offer you potential benefits, such as receiving a new medicine that could help with weight loss and related health conditions, along with close medical supervision. However, there are also potential risks, as any medicine can have side effects. These will be fully explained by the study team. You always have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (80)

Clinical Research Institute of Arizona (CRI) - Sun City West
Verified postcode
Sun City West, United States
Novak Clinical Research - Tucson - North La Cholla Boulevard
Verified postcode
Tucson, United States
Norcal Endocrinology & Internal Medicine
Verified postcode
San Ramon, United States
Southern California Clinical Research
Verified postcode
Santa Ana, United States
Care Access - Thousand Oaks
Verified postcode
Thousand Oaks, United States
Accel Research Sites - DeLand Clinical Research Unit
Verified postcode
DeLand, United States
Innovation Medical Research Center - Fort Lauderdale
Verified postcode
Fort Lauderdale, United States
Indago Research & Health Center, Inc
Verified postcode
Hialeah, United States
Encore Medical Research
Verified postcode
Hollywood, United States
West Orange Endocrinology P.A.
Verified postcode
Ocoee, United States
Care Access - Tampa
Verified postcode
Tampa, United States
Conquest Research
Verified postcode
Winter Park, United States

Common questions

What is orforglipron?

Orforglipron is an experimental medicine being tested to see if it can help people who are overweight or have obesity to lose weight.

What is a placebo?

A placebo is a dummy medicine. It looks exactly like the study medicine but doesn't contain any active ingredients. It helps researchers compare the effects of the real medicine.

How long does the study last?

If you join, your participation in this study will last for approximately 18 months.

Can I join if I have diabetes?

No, this study is not for people with any type of diabetes (Type 1 or Type 2).

What are 'weight-related comorbidities'?

These are health conditions that are often linked to being overweight or having obesity, such as high blood pressure, high cholesterol, or sleep apnoea.